Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). by Ayana Ablayeva (22103708)

Subjects:

Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments by Animesh Gopal (18521180)

Subjects:

The difference of BMD between 2019 and 2022 classify by grop of urinary camium levels measured in 2019. by Aroon La-up (14095691)

Subjects:

Non-linear relationship between urinary cadmium and bone mineral density from the adjusted restricted cubic splines model. by Aroon La-up (14095691)

Subjects:

Prevalence of osteoporosis classified by sex, and urinary cadmium level compare between 2019 and 2022. by Aroon La-up (14095691)

Subjects:

Linear Mixed-Effects Model analysis of bone mineral density changes in relation to urinary cadmium levels in a 3-Year Period. by Aroon La-up (14095691)

Subjects:

Data. by Aroon La-up (14095691)

Subjects:

Stratified analysis of the association between urinary cadmium and bone mineral density, by sex. by Aroon La-up (14095691)

Subjects:

Association between baseline urinary cadmium and the three-year change in bone mineral density (ΔBMD). by Aroon La-up (14095691)

Subjects:

Characteristics of the study participants for continuous variables. by Aroon La-up (14095691)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

S2 Appendix - by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. There was an overall decrease in State Trait Anxiety Inventory (STAI) scores of participants after counseling (p = 0.002) but no statistically difference in change of STAI scores between the two groups (p = 0.981).…”

Outcomes and interventions by group comparison. by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. There was an overall decrease in State Trait Anxiety Inventory (STAI) scores of participants after counseling (p = 0.002) but no statistically difference in change of STAI scores between the two groups (p = 0.981).…”